Clinically relevant GABARAP deficiency abrogates bortezomib-induced immunogenic cell death in multiple myeloma - Centre de recherche des Cordeliers Access content directly
Journal Articles OncoImmunology Year : 2024

Clinically relevant GABARAP deficiency abrogates bortezomib-induced immunogenic cell death in multiple myeloma

Abstract

Recently, it was revealed that the high-risk, poor-prognosis downregulation of GABA type A receptor-associated protein (GABARAP) causes a defect in both autophagy and surface exposure of calreticulin (CALR) in multiple myeloma (MM) cells responding to bortezomib. Hence, GABARAP-defective MM cells fail to undergo immunogenic cell death.
Fichier principal
Vignette du fichier
Clinically relevant GABARAP deficiency abrogates bortezomib-induced immunogenic cell death in multiple myeloma.pdf (984.15 Ko) Télécharger le fichier
Origin Publisher files allowed on an open archive

Dates and versions

hal-04601411 , version 1 (04-06-2024)

Identifiers

Cite

Liwei Zhao, Zhe Shen, Guido Kroemer, Oliver Kepp. Clinically relevant GABARAP deficiency abrogates bortezomib-induced immunogenic cell death in multiple myeloma. OncoImmunology, 2024, 13 (1), pp.2360275. ⟨10.1080/2162402X.2024.2360275⟩. ⟨hal-04601411⟩
36 View
5 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More